Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia

Abstract

Our results suggest that desmopressin is effective in the symptomatic management of nocturia in patients with MS and neurogenic detrusor overactivity. Maximal bladder capacity is a valuable predictor of response to desmopressin.

TVT vs. TOT: a comparison in terms of continence results, complications and quality of life after a median follow-up of 48 months

“…Treatment options for SUI include pelvic floor muscle training, lifestyle interventions, bladder retraining, pharmacotherapy, anti-incontinence devices and surgery [8][9][10]. The mid-urethral tension-free tape procedures have revolutionized incontinence surgery.…”

Group session teaching of behavioral modification program (BMP) for urinary incontinence: a randomized controlled trial among incontinent women

“…The options currently available have ranged from information campaigns with self-help literature, conservative management programs (for which BMP is one), chronic pharmaceutical prescriptions, and surgical interventions [16,17]. In a study conducted nationwide in the Netherlands with stress, urge, or mixed incontinence involving 530 women of all ages, it was concluded that individual and group physiotherapy are equally effective [8].…”

Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms

“…Common pharmacologic agents used to treat urinary symptoms include anticholinergics or beta 3 agonists for OAB, although there are few dedicated studies examining the efficacy of these medications in MS patients [18]. Desmopressin, in contrast, has some evidence supporting its use for treating nocturia in MS patients, particularly those with high maximum bladder capacity [19]. Although alpha blockers can be considered for treating urinary retention in MS patients, data is extremely limited.…”